Regeneron Pharmaceuticals major shareholder Buys $112,870,648 in Stock (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN) major shareholder Sanofi bought 397,264 shares of the company’s stock on the open market in a transaction dated Wednesday, February 5th. The stock was purchased at an average cost of $284.12 per share, with a total value of $112,870,647.68. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.82% during mid-day trading on Thursday, hitting $287.03. 661,049 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52-week low of $154.16 and a 52-week high of $319.83. The stock’s 50-day moving average is $280.9 and its 200-day moving average is $279.2. The company has a market cap of $28.194 billion and a price-to-earnings ratio of 40.13.
Several analysts have recently commented on the stock. Analysts at TheStreet reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Monday. Finally, analysts at BMO Capital Markets downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday, January 15th. They now have a $331.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $305.66.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.